QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive Recurrent Ovarian Cancer
Stopped A total of 204 patients were planned to be randomized. Due to slow recruitment of the trial, the recruitment was prematurely terminated after randomization of the 89th patient.
Conditions
- Quality of Life
- Ovarian Cancer
- Recurrent Ovarian Carcinoma
Interventions
- DRUG: Trabectidin (Yondelis)
Sponsor
North Eastern German Society of Gynaecological Oncology
Collaborators
- [object Object]
- [object Object]